Type 1 Diabetes News and Research

Latest Type 1 Diabetes News and Research

Merck announces data from MK-3102 Phase IIb trial on type 2 diabetes

Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.

4 Oct 2012

‘Hygiene hypothesis’ updated to ‘Old Friends’ hypothesis

A new scientific report out today from the International Scientific Forum on Home Hygiene (IFH) dismantles the myth that the epidemic rise in allergies in recent years has happened because we’re living in sterile homes and overdoing hygiene.

3 Oct 2012

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.

3 Oct 2012

New testing method for gestational diabetes

The increasingly common condition of gestational diabetes can have serious consequences for both the mother and child if left untreated. Prompt diagnosis and therapy can protect against these consequences. A new testing method developed at the MedUni Vienna now makes diagnosis easier and also cheaper.

3 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

2 Oct 2012

Omega-3 fatty acid supplements could slow key biological process linked to aging

Taking enough omega-3 fatty acid supplements to change the balance of oils in the diet could slow a key biological process linked to aging, new research suggests.

2 Oct 2012

WBC counts in diabetes risk prediction

An elevated white blood cell count in young men is an independent predictor for the development of diabetes in later life, suggest study findings.

1 Oct 2012

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.

28 Sep 2012

Alpha-glucosidases can be turned on and off, finds study

A study co-led by Simon Fraser University and Purdue University has found that the intestinal enzymes responsible for processing starchy foods can be turned on and off, helping to better control those processes in people with Type 2 diabetes.

28 Sep 2012

Two-part ACR guidelines on gout

Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).

28 Sep 2012

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.

27 Sep 2012

Type 2 diabetes may be derived from composition of specific intestinal flora

Whether you have an increased risk of developing type 2 diabetes, in the future may be derived from the composition of your intestinal flora. That according to new metagenomics research of an international consortium of scientists, including Jeroen Raes, connected to VIB and Vrije Universiteit Brussel. Metagenomics is the study of the genetic material of complete ecosystems, in this case the human intestine. This study appears in the leading journal Nature.

27 Sep 2012

MicroRNA processing in fat tissue plays a major role in aging and stress resistance

As part of their ongoing research investigating the biology of aging, the greatest risk factor for type 2 diabetes and other serious diseases, scientists at Joslin Diabetes Center have identified a new factor - microRNA processing in fat tissue - which plays a major role in aging and stress resistance.

27 Sep 2012

Karolinska Institutet scientists discover new approach to treat type II diabetes

An international team of scientists, led from Karolinska Institutet in Sweden, have discovered an entirely new approach to the treatment of type II diabetes. The therapy involves the blockade of signalling by a protein known as VEGF-B and this prevents fat from accumulating in the 'wrong' places, such as in muscles and in the heart. As a result the cells within these tissues are once again able to respond to insulin.

27 Sep 2012

CeQur completes PaQ Insulin Delivery Device clinical study on type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ Insulin Delivery Device.

27 Sep 2012

CSL develops new drug candidate against type 2 diabetes

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.

27 Sep 2012

Extended release exenatide outperforms twice daily regimen

Once-weekly extended-release exenatide is a more effective treatment than twice-daily exenatide at improving glucose control among Japanese individuals with diabetes, report researchers.

24 Sep 2012

Low aerobic fitness risk factor for chronic kidney disease in men

Young men with low levels of aerobic fitness are more likely to have albuminuria or glomerular hyperfiltration, both early signs of chronic kidney disease, than those with higher levels of fitness.

24 Sep 2012

Iron transport may contribute to diabetes

Scientists have been trying to explain the causes of diabetes for many years. Researchers at the University of Copenhagen and Novo Nordisk A/S have now shown that the increased activity of one particular iron-transport protein destroys insulin-producing beta cells. In addition, the new research shows that mice without this iron transporter are protected against developing diabetes.

21 Sep 2012